ArtVentive Medical has received US Food and Drug Administration (FDA) clearance for the Endoluminal Occlusion System (EOS). Designed for use in the peripheral vasculature, the EOS offers immediate, complete and total occlusion in arterial and venous settings.
Suresh Vedantham, professor of Radiology, Interventional Radiology Section, Washington University School of Medicine in St Louis, USA, spoke to Interventional News on the latest from the paper “Quality improvement guidelines for the treatment of lower-extremity deep vein thrombosis with use of endovascular thrombus removal” hot on the heels of its online publication in the Journal of Vascular and Interventional Radiology (JVIR).
“No matter what their future orientation, interventional radiologists involved in interventional oncology need to have a basic training in what is called ‘general interventional radiology’ in order to be able to provide a uniform and standardised care,” José Ignacio Bilbao Jaureguízar, professor and head of the Department of Interventional Radiology, Clínica Universitaria de Navarra, Pamplona, Spain, told Interventional News.
In a new consensus statement, the Joint UK Societies claim that the negative results of SYMPLICITY HTN-3 should not be used as a “rationale for abandoning” renal denervation as a “novel therapeutic development” for resistant hypertension because they claim more clinical trials are needed to evaluate the safety and efficacy of the therapy.
Results of the DISRUPT PAD study show that Lithoplasty, a new balloon-based technology, demonstrates safety and efficacy in the treatment of superficial femoral artery and popliteal artery disease. Early results with the technology were presented at a late-breaking trial session at the Vascular Interventional Advances conference (VIVA, 4–7 November, Las Vegas, USA).
Royal Philips has introduced the DoseWise Portal, a comprehensive radiation dose management software solution aimed at managing radiation exposure risk to patients and their caregivers.
The US Federal Trade Commission (FTC) and the European Commission have given clearance of Medtronic’s proposed acquisition of Covidien.
Silk Road Medical’s 30-day outcomes from the ROADSTER IDE study were presented at the Late Breaking Clinical Trials Session at the 2014 Vascular InterVentional Advances (VIVA) Meeting in Las Vegas, with additional data presented at the VEITHsymposium in New York.
The first large-scale, multispecialty prospective clinical research trial to evaluate the use of inferior vena cava (IVC) filters and related follow-up treatment in the USA – initiated by a collaboration between the Society of Interventional Radiology (SIR) and the Society for Vascular Surgery (SVS) – is set to enrol the first patient in spring 2015 with participation from seven filter manufacturers.
Hansen Medical has announced the completion of the first robotic prostatic artery embolisation (PAE) in the USA. Sandeep Bagla, interventional radiologist, performed the procedure at Inova Alexandria Hospital in Alexandria, Virginia using the Magellan robotic system.
CeloNova BioSciences has announced that the US FDA has granted approval to start an investigational device exemption (IDE) clinical trial for its Oncozene embolic microspheres, loaded with doxorubicin, a chemotherapy drug used in the treatment of hepatocellular carcinoma.
FREMONT, Calif., Nov. 19, 2014 -- (Healthcare Sales & Marketing Network) -- Cordis Corporation announced today the presentation of new data from the most recent clinical studies at the 2014 VEITHsymposium®, showcasing the company s diverse and strong endovascular technology portfolio. One of the featured Cordis podium presentations is the first-ever presentation of the three-year INCRAFT® AAA Stent Graft System (INCRAFT® System) Innovation study data.
Texas man is the world’s first to receive the PROTEK Duo for treatment following surgery
The Mediterranean diet is linked to improved cardiovascular performance in patients with erectile dysfunction, according to research presented at EuroEcho-Imaging 2014 by Dr Athanasios Angelis from Greece. Patients with erectile dysfunction who had poor adherence to the Mediterranean diet had more vascular and cardiac damage.
November 5, 2014—VIVA Physicians, Inc. announced that Eamon Dolan, MD, presented findings from the ROX-CONTROL HTN study during a late-breaking trials session at the VIVA 2014: Vascular InterVentional Advances meeting in Las Vegas, Nevada. The study is a randomized study evaluating the blood pressure-lowering effect of the Coupler device (Rox Medical, Inc.) in resistant hypertensive patients across European study sites.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos